EASTERN COOPERATIVE ONCOLOGY GROUP

东方肿瘤合作组

• 批准号: 2086302
• 负责人: Janice Phillips Dutcher
• 金额: $ 20.02万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-01 至 1999-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2086302
• 关键词: all trans retinol; biological response modifiers; bone marrow transplantation; breast neoplasms; cancer prevention; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; fluorouracil; gastrointestinal neoplasms; head /neck neoplasm; human subject; human therapy evaluation; interferon alpha; leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; paclitaxel; protooncogene; reproductive system neoplasm; urinary tract neoplasms

The Albert Einstein Cancer Center has been and continues to be a major scientific resource for ECOG, providing pilot study data for the initiation of new ECOG clinical trials and providing laboratory resources for correlative studies. During the past grant period, ECOG studies in lymphoma, leukemia, breast, head and neck, melanoma and GI malignancies have been initiated based on pilot work from Einstein. Two of Einstein's investigators have obtained RO1 funding for laboratory research related to ECOG clinical trials, and Einstein has initiated 3 laboratory-based correlative studies in the leukemias, 1 in colon cancer and 1 in cervical cancer with partial funding provided by Einstein itself. Einstein has developed 3 core laboratories for ECOG: 1) immunophenotyping reference lab; 2) molecular biology of differentiation related to retinoic acid in leukemia; and 3) molecular biology of bcr-abl in ALL. Einstein, as a tertiary care facility, has maintained its accrual level, with 167 patients entered (140 from main institution) from 7/1/91 -6/30/92, and 391 patients continuing in follow-up. Forty to 52% of patients entered into clinical trials at Einstein are from minority races which in part reflects the efforts made by the institution to recruit such patients into clinical research trials utilizing minority race staff to encourage participation. More than 50% of study participants are women, and Einstein has developed ECOG studies specifically for malignancies of women. An Einstein investigator is the chair of the Gyn Onc Working Group. Einstein investigators have chaired 13 ECOG studies during the past grant period and 5 Einstein investigators have held disease or modality committee leadership roles (chair or co-chair) during the last grant period. The Einstein CGOP, which includes another major university center (SUNY-Stonybrook) and a large hospital in Long island (Nassau County Medial Center) and one in the Bronx (Our Lady of Mercy) has been productive participants in ECOG, in terms of accrual to studies and groupwide meeting attendance.

阿尔伯特·爱因斯坦癌症中心一直是并将继续是一个 ECOG的主要科学资源，提供试点研究数据， 启动新的ECOG临床试验并提供实验室检查 相关研究资源。 在过去的赠款期间， 淋巴瘤、白血病、乳腺、头颈部、黑色素瘤的ECOG研究 和胃肠道恶性肿瘤已经启动的基础上试点工作， 爱因斯坦 爱因斯坦的两名研究人员已经获得了RO 1 资助与ECOG临床试验相关的实验室研究， 爱因斯坦发起了三项基于实验室的相关研究 白血病1例，结肠癌1例，宫颈癌1例， 部分资金由爱因斯坦自己提供。 爱因斯坦 为ECOG开发了3个核心实验室：1）免疫表型 参考实验室; 2）分化相关的分子生物学 白血病中bcr-abl的分子生物学 所有. 爱因斯坦，作为一个三级护理机构， 入组167例患者（140例来自主研究组） 从1991年7月1日至1992年6月30日，391例患者继续在 随访 40%至52%的患者进入临床试验 在爱因斯坦是从少数民族，这部分反映了 该机构为招募此类患者而做出的努力 利用少数民族工作人员进行临床研究试验， 参与的 超过50%的研究参与者是女性， 爱因斯坦专门针对恶性肿瘤开展了ECOG研究 对妇女一位爱因斯坦研究员是妇产科的主席， 工作组。 爱因斯坦研究人员主持了13项ECOG研究 在过去的资助期间，5名爱因斯坦研究人员举行了 疾病或模式委员会领导作用（主席或联合主席） 在最后一个补助期间。 Einstein CGOP包括 另一个主要的大学中心（SUNY-Stonybrook）和一个大型的 长岛的一家医院（拿骚县医疗中心）和 布朗克斯（仁慈圣母）一直是富有成效的参与者， ECOG，在研究和全组会议的累积方面 出席情况.